J Clin Med Res

Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access

Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc

Journal website http://www.jocmr.org

Case Report

Volume 3, Number 1, February 2011, pages 47-51

Talactoferrin Immunotherapy in Metastatic Renal Cell Carcinoma: A Case Series of Four Long-Term Survivors

Figures

Figure 1.. The regression of the tumor size (longest diameters) during the first 17 months of therapy in case 4.

Figure 2.. CT scans showing the reduction in size of the pulmonary metastases in case 4.

Table

**Table 1.** Additional Patients' Information
Sr. No.	1	2	3	4
Age at Entry	66	51	60	72
RhLF Dose	9 g/day	9 g/day	9 g/day	9 g/day
Histology	Clear cell	Clear cell	Clear, Spindle cell	Clear cell
Previous Therapy	nephrectomy	nephrectomy, IL-2, interferon-α	nephrectomy, IL2, interferon-α, methionine restriction	nephrectomy, Capecitabine, Gemcitabine, interferon-α, thalidomide
MSKCC Risk	Low	Low	Low	Low
Patient Status	Alive after 6 years	Alive after 5.5 years	Alive after 7.5 years	Died after 37 months
PFS (Months)	35	50	35	34